At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
18F-FETdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of the Utility of the Radiotracer "FET"in PET Imaging of Recurrent Glioblastoma Multiforme (GBM): Monitoring Early Response to Antiangiogenic Therapy
In Brief
A Phase 2 clinical trial evaluating 18F-FET for Glioblastoma Multiforme and GBM. Completed, enrolled 13 participants across 1 site.
Detailed Summary
Hypothesis: The central hypothesis underlying the proposed research study is that FET-PET will predict durable benefit in patients receiving anti-angiogenic benefit for presumed recurrent GBM (i.e. progression-free survival and overall survival). We have defined one primary specific aim, for which we expect to obtain definitive results, and two secondary aims, under which we plan to generate preliminary data to support a future, larger project.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma Multiforme, GBM
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 2012
Enrollment StartFeb 2013
Primary CompletionSep 2015
TodayJul 2026
First PostedDec 25, 2012
Enrollment StartFeb 1, 2013
Primary CompletionSep 13, 2015
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 13.5 years ago
Interventions
18F-FETdrug
Radiotracer, surrogate marker for protein synthesis